ReviewActa pharmaceutica Sinica. B2020
Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Abstract readReview
In one paragraph
Review in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.
0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed.
- Beyond chemotherapy: The rise of nucleic acid nanoformulations in personalized lung cancer therapy.Cancer pathogenesis and therapy · 2026Review
- Precision Nanotechnology: Revolutionizing Therapeutic Strategies Against Drug-Resistant Breast Cancer.Annals of biomedical engineering · 2026Review
- High-Throughput Generation of Tumor Spheroids via Droplet Microfluidics for siRNA-Loaded Nanomedicine Assessment.Advanced healthcare materials · 2026Article
- Titanium dioxide nanoparticles in oncology: synthesis, application, and challenges.Cell biology and toxicology · 2026Review
- Thermoreversibly assembled polymersomes for highly efficient loading, processing and delivery of protein and siRNA biologics.Nature biomedical engineering · 2026Article
- Interferon-stimulated gene 15 small interfering RNA-loaded polarized mesoporous silica nanocarriers remodel the immune microenvironment to ameliorate post-myocardial infarction heart failure.Materials today. Bio · 2026Article
- ROR1 protein: a pseudokinase at the crossroads of cancer progression and therapy.Molecular biology reports · 2026Review
- The progress and perspective of nanomedicine in modulating the tumor immune microenvironment.Acta pharmaceutica Sinica. B · 2026Review
- Polymeric Nanomedicines for siRNA Delivery in Hepatocellular Carcinoma: Emerging Therapeutic Strategies, Combination Approaches, and Translational Perspectives.International journal of nanomedicine · 2026Review
- A smart nanocomposite bioactive ink for controlled siRNA delivery in calvarial mesenchymal stromal cells as a minimally invasive treatment for craniosynostosis.Regenerative biomaterials · 2026Article
- Peptide-modified phase-transition nanoparticles co-deliver FTO siRNA and Ce6 for sonodynamic metabolism-immunotherapy of melanoma.Journal of nanobiotechnology · 2025Article
- Interplay Between MicroRNAs and Breast Cancer Therapies: Personalized Therapeutic Potential for HER2-Low Breast Cancer.Cancers · 2025Review
- Inhibition of ARH2 by pH/ROS-responsive nanosystem for improved lung adenocarcinoma immunochemotherapy.Bioactive materials · 2025Article
- Research Progress on Nasal Delivery of siRNA Nanocarrier Systems for the Treatment of Neurodegenerative Diseases.Pharmaceutics · 2025Review
- Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- siRNA and mRNA-Based Preventive and Therapeutic Strategies for HPV-Induced Cervical Cancer.Advanced pharmaceutical bulletin · 2025Review
- Fabrication of RIG-I-Activating Nanoparticles for Intratumoral Immunotherapy via Flash Nanoprecipitation.Molecular pharmaceutics · 2025Article
- The Role of PIWI-Interacting RNA in Urologic Carcinoma and Its Clinical Implications.Cancer reports (Hoboken, N.J.) · 2025Review
- Smart magnetic nanoparticles under electromagnetic stimulation: a synergistic approach to targeted chemotherapy and hyperthermia.Nanomedicine (London, England) · 2025Review
- Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2025Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Nitin Bharat CharbeDepartamento de Quimica Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.
Nikhil D AmnerkarAdv V. R. Manohar Institute of Diploma in Pharmacy, Nagpur, Maharashtra 441110, India.
B RameshSri Adichunchunagiri College of Pharmacy, Sri Adichunchunagiri University, BG Nagar, Karnataka 571418, India.
Murtaza M TambuwalaSchool of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK.
Hamid A BakshiSchool of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK.
Alaa A A AljabaliFaculty of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 21163, Jordan.
Saurabh C KhadseDepartment of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education and Research, Dist. Dhule, Maharashtra 425 405, India.
Rajendran SatheeshkumarDepartamento de Quimica Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.
Saurabh SatijaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.
Meenu MethaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.
Dinesh Kumar ChellappanDepartment of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia.
Garima ShrivastavaDepartment of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Delhi, New Delhi 110016, India.
Gaurav GuptaSchool of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur 302017, India.
Poonam NegiSchool of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173229, India.
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.
Flavia C ZacconiDepartamento de Quimica Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.
Indexed as
1,3-propanediol, PEG-b-PDMAEMA-b-Ppy2-propylacrylicacid, PAH-b-PDMAPMA-b-PAHAPOB, apolipoprotein BAQP-5, aquaporin-5Atufect01, β-l-arginyl-2,3-l-diaminopropionicacid-N-palmityl-N-oleyl-amide trihydrochlorideAuNPs, gold nanoparticlesAZEMA, azidoethyl methacrylateBMA, butyl methacrylateB-PEI, branched polyethlenimineCancerCFTR, cystic fibrosis transmembrane conductance regulator geneCHEMS, cholesteryl hemisuccinateCHOL, cholesterolCMC, critical micelles concentrationDC-Chol, 3β-[N-(N′,N′-dimethylaminoethane)carbamoyl]cholesterolDMAEMA, 2-dimethylaminoethyl methacrylateDNA, deoxyribonucleic acidDOPC, dioleylphosphatidyl cholineDOPE, dioleylphosphatidyl ethanolamineDOTAP, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfateDOTMA, N-[1-(2,3-dioleyloxy)propy]-N,N,N-trimethylammoniumchlorideDOX, doxorubicinDSGLA, N,N-dis-tearyl-N-methyl-N-2[N′-(N2-guanidino-l-lysinyl)] aminoethylammonium chlorideDSPC, 1,2-distearoyl-sn-glycero-3-phosphocholineDSPE, 1,2-distearoyl-sn-glycero-3-phosphorylethanolamineDSPE-MPEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt)DSPE-PEG-Mal: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (mmmonium salt), EPRenhanced permeability and retention, Galnachypoxia-inducible factor-1α, KSPkinesin spindle protein, LDIlipid-protamine-DNA/hyaluronic acid, MDRLiposomeslysine ethyl ester diisocyanate, LPD/LPHmessenger RNA, MTXmethotrexate, NIRmethoxypoly(ethylene glycol), MPEG-PCLmethoxy polyethylene glycol-polycaprolactone, mRNAMicellesmicro RNA, MPEGmultiple drug resistance, MiRNAN-acetylgalactosamine, HIF-1αNanomedicinenanoparticle, NRP-1near-infrared, NPneuropilin-1, PAAPE-PCL-b-PNVCL, pentaerythritol polycaprolactone-block-poly(N-vinylcaprolactam)PiRNA, piwi-interacting RNAPLA, poly-l-argininePLGA, poly lactic-co-glycolic acidPLK-1, polo-like kinase 1PLL, poly-l-lysinepoly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine), PCLpolycaprolactone-polyethyleneglycol, PCL-PEG-PHISpolycaprolactone-polyethylenimine, PDMApoly(ethylene glycol)-block-poly(2-dimethylaminoethyl methacrylate)-block poly(pyrenylmethyl methacrylate), PEG-b-PLLpoly(ethylene glycol)-block-poly(l-lysine), PEIpoly(ethylene oxide)-block-poly(2-(diethylamino)ethyl methacrylate)-stat-poly(methoxyethyl methacrylate), PEO-b-PCLpoly(ethylene oxide)-block-poly(Ε-caprolactone), PE-PCL-b-PNIPAMpolyethylenimine, PEO-b-P(DEA-Stat-MEMAPolymerpoly(N-isopropyl acrylamide), pentaerythritol polycaprolactone-block-poly(N-isopropylacrylamide)poly(N,N-dimethylacrylamide), PDOpoly(Ε-caprolactone), PCL-PEGpoly(Ε-caprolactone)-polyethyleneglycol-poly(l-histidine), PCL-PEIPPES-b-PEO-b-PPES, poly(4-(phenylethynyl)styrene)-block-PEO-block-poly(4-(phenylethynyl)styrene)PTX, paclitaxelRES, reticuloendothelial systemRGD, Arg-Gly-Asp peptideRISC, RNA-induced silencing complexRNAi, RNA interferenceRNA, ribonucleic acidRNAse III, ribonuclease III enzymeS–Au, thio‒goldSEM, scanning electron microscopeSiRNA, short interfering rNASmall interfering RNA (siRNA)SNALP, stable nucleic acid-lipid particlesTCC, transitional cell carcinomaTEM, transmission electron microscopyTf, transferrinTrka, tropomyosin receptor kinase AUSPIO, ultra-small superparamagnetic iron oxide nanoparticlesUV, ultravioletVEGF, vascular endothelial growth factorZEBOV, Zaire ebola virus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.